FDA Approved: MULTIHANCE — Supplemental Application (BRACCO DIAGNOSTICS INC)

View source ↗

Summary

The FDA approved a supplemental application for MULTIHANCE (gadobenate dimeglumine) to update its labeling and imaging indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Hepatocellular Carcinoma
• Liver Metastases

Drugs mentioned

• MULTIHANCE (Gadobenate dimeglumine)

Snippet

SUPPL AP for MULTIHANCE (GADOBENATE DIMEGLUMINE)